Payload Information

General Information of This Payload

Payload ID	PAY0ZHBNS
Name	GRM cpd 32
Synonyms	GRM cpd 32 Click to Show/Hide
Target(s)	Glucocorticoid receptor (NR3C1)			Target Info
Structure
Structure	3D MOL		2D MOL
Formula	C34H35F2NO6S
Isosmiles	CC12C=CC(=O)C=C1C(F)CC1C3CC4OC(c5ccc(SCc6cccc(N)c6)cc5)OC4(C(=O)CO)C3CC(O)C12F
InChI	InChI=1S/C34H35F2NO6S/c1-32-10-9-21(39)12-26(32)27(35)14-25-23-13-30-33(29(41)16-38,24(23)15-28(40)34(25,32)36)43-31(42-30)19-5-7-22(8-6-19)44-17-18-3-2-4-20(37)11-18/h2-12,23-25,27-28,30-31,38,40H,13-17,37H2,1H3
InChIKey	UJBTWELKVGLDLW-UHFFFAOYSA-N
Pharmaceutical Properties	Molecule Weight	623.718	Polar area	119.08
	Complexity	44	xlogp Value	4.8139
	Heavy Count	44	Rot Bonds	6
	Hbond acc	8	Hbond Donor	3

The activity data of This Payload

Standard Type	Value	Units	Cell line	Disease Model	Cell line ID	Reference
Glucocorticoid response element reporter EC50	0.0001±0.0001	uM	Undisclosed	Undisclosed	Undisclosed	[1]
Glucocorticoid Receptor binding IC50	0.009±0.008	uM	Undisclosed	Undisclosed	Undisclosed	[1]

Each Antibody-drug Conjugate Related to This Payload

Full Information of The Activity Data of The ADC(s) Related to This Payload

Anti-TNF ADC 132 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.20 ng/mL	Positive TNF expression (TNF+++/++)
Method Description	All the DAR purified ADCs were screened in both the TNF-expressing and wild-type K562 GRE reporter cell assay to confirm that their activity was consistent with ADCs having heterogeneous average DAR.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells (TNF expression)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	12.10 ug/mL	Negative TNF expression (TNF-)
Method Description	All the DAR purified ADCs were screened in both the TNF-expressing and wild-type K562 GRE reporter cell assay to confirm that their activity was consistent with ADCs having heterogeneous average DAR.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

Anti-TNF ADC 133 [Investigative]

ADC Info

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	0.03 ug/mL	Positive TNF expression (TNF+++/++)
Method Description	All the DAR purified ADCs were screened in both the TNF-expressing and wild-type K562 GRE reporter cell assay to confirm that their activity was consistent with ADCs having heterogeneous average DAR.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells (TNF expression)		CVCL_0004
Experiment 2 Reporting the Activity Date of This ADC					[2]
Efficacy Data	Half Maximal Effective Concentration (EC50)	2.80 ug/mL	Negative TNF expression (TNF-)
Method Description	All the DAR purified ADCs were screened in both the TNF-expressing and wild-type K562 GRE reporter cell assay to confirm that their activity was consistent with ADCs having heterogeneous average DAR.
In Vitro Model	Chronic myelogenous leukemia	K-562 cells		CVCL_0004

References

Ref 1	Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate. J Med Chem. 2022 Dec 8;65(23):15893-15934.
Ref 2	Discovery of ABBV-3373, an Anti-TNF Glucocorticoid Receptor Modulator Immunology Antibody Drug Conjugate. J Med Chem. 2022 Dec 8;65(23):15893-15934.